GDX-012

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameGDX-012
Drug Alias Nameallogeneic, nongene-edited variable delta 1 gamma-delta T-cell therapyGDX012 (allogeneic blood-derived Vδ1+ T cell)GDX-012
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, AcuteLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGammaDelta Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co LtdGammaDelta Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, AcuteLeukemia

Other Information

ATC CodeN/A
Related LinksN/A